International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2545 - 2545

Published: March 12, 2025

The poor prognosis for high-grade serous ovarian cancer (HGSOC), the dominant subtype of cancer, reflects its aggressive nature, late diagnosis, and highest mortality rate among all gynaecologic cancers. Apart from main reason unsuccessful treatment is primarily emergence chemoresistance to carboplatin. Although there a good response primary treatment, disease recurs in 80% cases, at which point it largely resistant introduction novel targeted therapies second decade 21st century has begun transform HGSOC, although their impact on overall survival remains unsatisfactory. Targeting specific pathways known be abnormally activated HGSOC especially difficult due molecular diversity subtypes. Moreover, range changes are associated with acquired chemoresistance, e.g., reversion BRCA1 BRCA2 germline alleles. In this review, we examine advantages disadvantages approved therapies, including bevacizumab, PARP inhibitors (PARPis), treatments targeting cells neurotrophic tyrosine receptor kinase (NTRK), B-rapidly accelerated fibrosarcoma (BRAF), rearranged during transfection (RET) gene alterations, as well antibody–drug conjugates. Additionally, explore promising new targets under investigation ongoing clinical trials, such immune checkpoint inhibitors, anti-angiogenic agents, phosphatidylinositol-3-kinase (PI3K) Wee1 ataxia telangiectasia Rad3-related protein (ATR) platinum-resistant disease. Despite development carboplatin fundamental medicine therapy. correct choice strategy better patients advanced should therefore include prediction patients’ risks developing platinum-based chemotherapy. effective therapy requires selection who likely derive benefit while minimizing potential adverse effects, underscoring essence precision medicine.

Language: Английский